Pharmacoeconomic implications of thromboprophylaxis with new oral anticoagulants after total hip or knee replacement in the USA

Bibliography

• Baser O, Supina D, Sengupta N, Clinical and cost outcomes of venous thromboembolism in Medicare patients undergoing total hip replacement or total knee replacement surgery. Curr Med Res Opin 2011;27:423-9
   PubMed Web of Science ®Google Scholar
• Falck-Ytter Y, Francis CW, Johanson N, Prevention of VTE in Orthopedic Surgery Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(Suppl):e278S-e3255S
   PubMedGoogle Scholar
• Tapson VF. Acute pulmonary embolism. N Engl J Med 2008;358:1037-52
   PubMed Web of Science ®Google Scholar
• Kearon C. Natural history of venous thromboembolism. Circulation 2003;107:I22-30
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. State Medicaid Director Letter. 2008. Available from: www.cms.hhs.gov/SMDL/downloads/SMD073108.pdf [Last accessed 14 July 2012]
   Google Scholar
• Nutescu EA. Characteristics of novel anticoagulants and potential economic implications. Am J Manag Care 2011;17:S27-32
   PubMed Web of Science ®Google Scholar
• Warwick D, Samama MM. The contrast between venographic and clinical endpoints in trials of thromboprophylaxis in hip replacement. J Bone Joint Surg Br 2000;82:480-2
   PubMedGoogle Scholar
• MacDougall DA, Feliu AL, Boccuzzi SJ, Lin J. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm 2006;63:S5-S15
   PubMed Web of Science ®Google Scholar
• Pengo V, Lensing AW, Prins MH, Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:2257-64
   PubMed Web of Science ®Google Scholar
• Edelsberg J, Ollendorf D, Oster G. Venous thromboembolism following major orthopedic surgery: review of epidemiology and economics. Am J Health Syst Pharm 2001;58(Suppl 2):S4-S13
   PubMedGoogle Scholar
• Ollendorf DA, Vera-Llonch M, Oster G. Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients. Am J Health Syst Pharm 2002;59:1750-4
   PubMed Web of Science ®Google Scholar
• Dobesh PP. Economic burden of venous thromboembolism in hospitalized patients. Pharmacotherapy 2009;29:943-53
   PubMed Web of Science ®Google Scholar
• Bullano MF, Willey V, Hauch O, Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm 2005;11:663-73
   PubMedGoogle Scholar
• Oster G, Ollendorf DA, Vera-Llonch M, Economic consequences of venous thromboembolism following major orthopedic surgery. Ann Pharmacother 2004;38:377-82
   PubMed Web of Science ®Google Scholar
• Warwick D, Friedman RJ, Agnelli G, Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br 2007;89:799-807
   PubMed Web of Science ®Google Scholar
• Buller HR, Sohne M, Middeldorp S. Treatment of venous thromboembolism. J Thromb Haemost 2005;3:1554-60
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Comerota AJ, Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis. American College of Chest Physicians evidence-based clinical practice guidelines (9th edition). Chest 2012;141(Suppl):e419S-94S
   PubMedGoogle Scholar
• O'Brien JA, Caro JJ. Direct medical cost of managing deep vein thrombosis according to the occurrence of complications. Pharmacoeconomics 2002;20:603-15
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Kahn SR, Davidson BL, Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics 2003;21:477-96
   PubMed Web of Science ®Google Scholar
• Spyropoulos A, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007;13:475-86
   PubMed Web of Science ®Google Scholar
• Kahn SR. The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis. J Thromb Thrombolysis 2006;21:41-8
   PubMed Web of Science ®Google Scholar
• Ashrani AA, Heit JA. Incidence and cost burden of post-thrombotic syndrome. J Thromb Thrombolysis 2009;28:465-76
   PubMed Web of Science ®Google Scholar
• Caprini JA, Botteman MF, Stephens JM, Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health 2003;6:59-74
   PubMed Web of Science ®Google Scholar
• Davidson BL, Sullivan SD, Kahn SR, The economics of venous thromboembolism prophylaxis: a primer for clinicians. Chest 2003;124:393S-6S
   PubMed Web of Science ®Google Scholar
• Ageno W, Gallus AS, Wittkowsky A, Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, American College of Chest Physicians evidence-based clinical practice guidelines (9th edition). Chest 2012;141(Suppl):e44S-88S
   PubMed Web of Science ®Google Scholar
• Nutescu EA, Bathija S, Sharp LK, Anticoagulation patient self-monitoring in the United States: considerations for clinical practice adoption. Pharmacotherapy 2011;31:1232-49
   PubMed Web of Science ®Google Scholar
• Menzin J, Boulanger L, Hauch O, Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study. Ann Pharmacother 2005;39:446-51
   PubMed Web of Science ®Google Scholar
• Anderson RJ. Cost analysis of a managed care decentralized outpatient pharmacy anticoagulation service. J Manag Care Pharm 2004;10:159-65
   PubMedGoogle Scholar
• van Walraven C, Jennings A, Oake N, Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006;129:1155-66
   PubMed Web of Science ®Google Scholar
• Lieberman JR, Hsu WK. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am 2005;87:2097-112
   PubMed Web of Science ®Google Scholar
• Matzsch T. Thromboprophylaxis with low-molecular-weight heparin: economic considerations. Haemostasis 2000;30(Suppl 2):141-5
   PubMedGoogle Scholar
• Menzin J, Colditz GA, Regan MM, Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 1995;155:757-64
   PubMed Web of Science ®Google Scholar
• Bergqvist D, Lindgren B, Matzsch T. Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin. Br J Surg 1996;83:1548-52
   PubMed Web of Science ®Google Scholar
• Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009;15(Suppl 1):9S-16S
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim International GmbH. Pradaxa (dabigatran etexilate) summary of product characteristics. 2010. Available from: www.medicines.org.uk/emc/medicine/20760 [Last accessed 14 July 2011]
   Google Scholar
• Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009;48:1-22
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N, Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-56
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N, Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-85
   PubMed Web of Science ®Google Scholar
• The RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1-9
   Web of Science ®Google Scholar
• Xarelto [package insert]. Janssen Pharmaceuticals, Inc; Titusville, NJ: 2011
   Google Scholar
• Eriksson BI, Borris LC, Friedman RJ, Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75
   PubMed Web of Science ®Google Scholar
• Lassen MR, Ageno W, Borris LC, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86
   PubMed Web of Science ®Google Scholar
• Turpie AG, Lassen MR, Davidson BL, RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673-80
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Brenner B, Dahl OE, Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-9
   PubMed Web of Science ®Google Scholar
• Turpie AGG, Lassen MR, Eriksson BI, Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011;105:444-53
   PubMed Web of Science ®Google Scholar
• Raghavan N, Frost CE, Yu Z, Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009;37:74-81
   PubMed Web of Science ®Google Scholar
• Carreiro J, Ansell J. Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict. Expert Opin Investig Drugs 2008;17:1937-45
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A, Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361:594-604
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A, Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010;375:807-15
   PubMed Web of Science ®Google Scholar
• Lassen MR, Gallus A, Raskob GE, Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010;363:2487-98
   PubMed Web of Science ®Google Scholar
• de Pablo P, Losina E, Phillips CB, Determinants of discharge destination following elective total hip replacement. Arthritis Rheum 2004;51:1009-17
   PubMed Web of Science ®Google Scholar
• Bradley-Kennedy C, Wolowacz SE, Roskell NS, Plumb JM. Cost-effectiveness of dabigatran etexilate in Canada for the primary prevention of venous thromboembolism in patients undergoing total hip replacement surgery. J Thromb Haemost 2009;7:786
   Google Scholar
• Wolowacz SE, Roskell NS, Maciver F, Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther 2009;31:194-212
   PubMed Web of Science ®Google Scholar
• Wolowacz SE, Roskell NS, Plumb JM, Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. Thromb Haemost 2010;103:360-71
   PubMed Web of Science ®Google Scholar
• Bouee S, Zufferey P, Fagnani F. Budget impact analysis of Pradaxa thromboprophylaxis after total hip or total knee replacement. Therapie 2009;64:249-57
   PubMed Web of Science ®Google Scholar
• Kwong LM. Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty. Am J Manag Care 2011;17:S22-6
   PubMed Web of Science ®Google Scholar
• Friedman R, Lees M, Sengupta N, Haas S. Rivaroxaban for prevention of venous thromboembolism after total hip replacement: impact on healthcare costs based on the RECORD1 study [abstract]. J Bone Joint Surg Br 2008;92B(Suppl 2):288
   Google Scholar
• Kwong LM, Diamantopoulos A, Forster F, Will rivaroxaban be cost-effective for prevention of venous thromboembolism after total hip replacement in US patients? Blood (ASH Annual Meeting Abstracts) 2008;112:abstract 1290
   Web of Science ®Google Scholar
• Quinlan DJ, Eikelboom JW, Dahl OE, Association between asymptomatic deep-vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J Thromb Haemost 2007;5:1438-43
   PubMed Web of Science ®Google Scholar
• McGarry LJ, Thompson D, Weinstein MC, Goldhaber SZ. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. Am J Manag Care 2004;10:632-42
   PubMed Web of Science ®Google Scholar
• Friedman RJ, Gallus AS, Cushner FD, Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin 2008;24:87-97
   PubMed Web of Science ®Google Scholar
• Duran A, Sengupta N, Diamantopoulos A, Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective. Pharmacoeconomics 2012;30(2):87-101
   PubMed Web of Science ®Google Scholar
• Diamantopoulos A, Lees M, Wells PS, Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thromb Haemost 2010;104:760-70
   PubMed Web of Science ®Google Scholar